KemPharm Inc., a Coralville-based specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity prodrugs, began trading today on the NASDAQ Global Market under the ticker symbol KMPH. The company’s initial public offering of more than 5 million shares of common stock was priced at $11 per share and at midday shares were trading at $11.94. KemPharm has granted the underwriters a 30-day option to purchase up to 763,636 additional shares of common stock from KemPharm. The offering is expected to close on April 21. KemPharm’s most advanced product candidate is a prodrug equivalent to hydrocodone for the treatment of moderate to moderately severe pain.